Apremilast
Apremilast is an active ingredient of the class «immunosuppressive drug».
Chemical compound
What it is used for
- Arthritis
- Psoriasis
- Psoriatic arthritis
- Ankylosing spondylitis
- Osteoarthritis susceptibility 1
- Psoriasis-related juvenile idiopathic arthritis
- Guttate psoriasis
- Multiple sclerosis
- Behçet's disease
- Immune disorder
- Mouth ulcer
OTEZLA/OTEZLA XR, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of: Adult patients with: Active psoriatic arthritis Plaque psoriasis who are candidates for phototherapy or systemic therapy Oral ulcers associated with Behçet's Disease Pediatric patients 6 years of age…
Psoriatic arthritisOtezla, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.
How it works
- Phosphodiesterase 4 inhibitor
Class: immunosuppressive drug
Common side effects
The following adverse reactions are described elsewhere in the labeling: Hypersensitivity Diarrhea, Nausea, and Vomiting Depression Weight Decrease Drug Interactions Psoriatic Arthritis: The most common adverse reactions (≥ 5%) are diarrhea, nausea, and headache Plaque Psoriasis: The most common adverse reactions (≥…
Who should not take it
OTEZLA/OTEZLA XR is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation. Known hypersensitivity to apremilast or to any of the excipients in the formulation
Pregnancy and breastfeeding
Available data with OTEZLA use in pregnant women have not identified a drug-associated risk of major birth defects or adverse maternal or fetal outcomes.
Interactions
Brand names
United States
Otezla · Otezla XR
European Union
Apremilast Accord · Otezla
Canada
Accel-Apremilast · Apo-Apremilast · Auro-Apremilast · Jamp Apremilast · Mar-Apremilast · Otezla · Pms-Apremilast · Sandoz Apremilast
Approval status
- US Food and Drug Administration
- prescription · since 2014
- European Medicines Agency
- authorised · since 2015
- Health Canada
- prescription · marketed
- First approval anywhere
- 2014
Codes
- ATC
- L04AA32
- RxNorm CUI
- 1492727
- ChEMBL
- CHEMBL514800
- PubChem CID
- 11561674
- UNII
- UP7QBP99PN
- Wikidata
- Q2858961
Frequently asked questions
What is Apremilast used for?
Apremilast is used for: Arthritis, Psoriasis, Psoriatic arthritis, Ankylosing spondylitis, Osteoarthritis susceptibility 1, Psoriasis-related juvenile idiopathic arthritis, Guttate psoriasis, and Multiple sclerosis.
What kind of medicine is Apremilast?
Apremilast is an active ingredient of the class «immunosuppressive drug».
What are the brand names of Apremilast?
Brand names of Apremilast include Otezla, Otezla XR, Apremilast Accord, Accel-Apremilast, Apo-Apremilast, Auro-Apremilast, Jamp Apremilast, and Mar-Apremilast.
Medicines in the same class
- Sirolimus
- Adalimumab
- Everolimus
- Leflunomide
- Fingolimod
- Cladribine
- Teriflunomide
- Tofacitinib
- Mycophenolate mofetil
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)